GlassScriptPhysician profile
Wilson C Sy
NPI 1588726749
$9,317.01
in general payments reported to CMS, 2019-2025
27 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $3,028 · 2021: $1,407 · 2022: $2,467 · 2023: $801 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $2,160.00 | 2020 | |
| Supernus Pharmaceuticals, INC. | $1,379.41 | 2019-2025 | Qelbree, Qelbree |
| Neurelis, INC. | $1,240.55 | 2020-2023 | Valtoco |
| Ucb, INC. | $1,131.62 | 2019-2023 | Briviact |
| Ironshore Pharmaceuticals INC. | $489.14 | 2019-2023 | Jornay Pm |
| Eisai INC. | $472.62 | 2020-2023 | |
| Sk Life Science, INC. | $402.40 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $270.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.60 | 2020-2022 | |
| Corium, LLC | $219.37 | 2022-2023 | Azstarys |
| Livanova USA, INC. | $205.99 | 2019 | |
| Zogenix INC. | $175.83 | 2021 | |
| Tris Pharma INC | $172.02 | 2019-2023 | Dyanavel Xr |
| Greenwich Biosciences, INC. | $143.55 | 2019-2021 | |
| Biogen, INC. | $124.68 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $82.87 | 2019-2023 | Diacomit |
| Immedica Pharma US, INC. | $75.17 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $69.88 | 2023 | Aptiom |
| Upsher-Smith Laboratories LLC | $47.94 | 2019 | |
| Shire North American Group INC | $41.56 | 2019 | |
| Biomarin Pharmaceutical INC. | $39.29 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $32.77 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $24.82 | 2023 | Fycompa |
| Ptc Therapeutics, INC. | $23.55 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.64 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.